Single-cell RNA-sequencing of colorectal cancer PDOX tumors treated with vehicle or the TROP2-targeting antibody-drug conjugate Sacituzumab Govitecan
Patient-derived colorectal cancer organoids were injected into mice to grow into subcutaneous tumors. Starting at 100 mm3, tumors were treated with Trodelvy (Sacituzumab Govitecan (SG)) or vehicle twice per week for 28 days before samples were harvested and subjected to single-cell RNA-sequencing of the tumor cells.